Articles tagged "Liver"

2019 American Transplant Congress
Cholecystitis in High-Acuity Patients Undergoing Liver Transplantation: A Five-Year Analysis of Incidence, Causes and Impact
D. S. Graham, T. Ito, M. M. Lu, J. DiNorcia, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas
Dumont-UCLA Liver Transplant Center, Department of Surgery, UCLA School of Medicine, Los Angeles, CA
*Purpose: While the incidence of gallbladder pathology is well described in the general population, there is almost no data on cholecystitis in liver transplant candidates…
2019 American Transplant Congress
Outcomes for Lung Transplantation Recipients with Non-Alcoholic Fatty Liver Disease
A. J. Trindade¹, P. Burkett¹, S. El-Chemaly¹, N. Hashemi², T. Thaniyavarn¹, H. R. Mallidi³, H. J. Goldberg¹
¹Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ²Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, ³Division of Thoracic and Cardiovascular Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Non-alcoholic Fatty Liver Disease (NAFLD) afflicts ~20-40% people in the western world and is a risk factor for comorbidities prevalent in the lung transplant…
2019 American Transplant Congress
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious
P. Brown¹, Z. Demertzis¹, S. Jafri²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI
*Purpose: Chronic HCV is one of the leading causes for end stage liver disease and liver transplantation. Since their introduction, DAAs have revolutionized the treatment…
2019 American Transplant Congress
The Increasing Financial Challenge of Liver Transplantation
D. Axelrod¹, S. Hohmann², K. Lentine³, H. Xiao³, B. Kasiske⁴, J. Snyder⁴, M. Ostrander⁵, M. Schnitzler³
¹Univ of Iowa, Iowa City, IA, ²Vizient Inc, Chicago, IL, ³Saint Louis Univ, St. Louis, MO, ⁴SRTR, Minneapolis, MN, ⁵Visient, Inc., Minneapolis, IA
*Purpose: Despite innovations in clinical care, liver transplant (LT) remains highly resource intensive due to medical complexity and organ quality. National allocation systems prioritize access…
2019 American Transplant Congress
The Economic Impact of Surgical Site Infections in Liver Transplantation
Y. Natori¹, D. Kumar², A. Humar², S. Husain², C. Rotstein³
¹Miami Transplant Institute, University of Miami, Miami, FL, ²Transplant Infectious Diseases, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
*Purpose: Complications arising after liver transplantation result in additional healthcare costs. Previous studies have not evaluated the impact of surgical site infections on healthcare costs…
2019 American Transplant Congress
Hepatopancreatobiliary Training In Transplant Fellowships: H And B, Maybe?
R. Borscheid¹, A. Saharia², E. Cho¹, F. Lewis¹, H. Osman¹, J. Kurtz¹, D. Jeyarajah¹, A. Gaber²
¹Methodist Richardson Medical Center, Richardson, TX, ²Houston Methodist Hospital, Houston, TX
*Purpose: HPB surgery is an evolving specialty, but only about 15% of the active HPB surgeons have undergone training in a dedicated HPB program -…
2019 American Transplant Congress
Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation
J. Wellington¹, A. Ma², S. Kottilil³, J. Husson³, E. Wilson³, D. Bruno⁴
¹Gastroenterology & Hepatology, University of Maryland, Baltimore, MD, ²Internal Medicine, University of Maryland, Baltimore, MD, ³Institute of Human Virology, Division of Clinical Care and Research, University of Maryland, Baltimore, MD, ⁴Transplant Surgery, University of Maryland, Baltimore, MD
*Purpose: Liver transplantation, LT, for HCV-related disease has the lowest five-year graft survival of all LT recipients, primarily due to accelerated fibrosis from unrestrained HCV…
2019 American Transplant Congress
IgG4 Subclass Class 2 Donor Specific Antibody (DSA) is Associated with Subclinical Rejection in Stable Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests
A. Jackson¹, S. Kanaparthi², B. Burrell³, D. Lucas⁴, R. Vega⁴, A. J. Demetris⁵, S. Feng⁶
¹Surgery, Duke University, Durham, NC, ²The Immune Tolerance Network, Bethesda, MD, ³Immune Tolerance Network, Bethesda, MD, ⁴Medicine, Johns Hopkins University, Baltimore, MD, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA, ⁶Surgery, University of California San Francisco, San Francisco, CA
*Purpose: DSA is a known biomarker of allograft rejection, yet injury phenotype and potential differ across organs. Among pediatric LT recipients entering iWITH (NCT01638559), an…
2019 American Transplant Congress
Use of Marginal Liver Donors in Pediatric Transplantation: Diverse Profiles of Use in Major Transplant Centers
C. S. Hwang¹, A. Aqul², A. Mufti³, S. Hanish¹, D. Desai¹, P. Vagefi¹, M. MacConmara¹
¹Surgery, UT Southwestern, Dallas, TX, ²Pediatrics, UT Southwestern, Dallas, TX, ³Medicine, UT Southwestern, Dallas, TX
*Purpose: Pediatric liver transplantation is highly specialized only a small number of centers have consistent large volume experience. We tested the hypothesis that large volume…
2019 American Transplant Congress
The Impact of Thrombin / Protease-Activated Receptor-1 Pathway in Hepatic Ischemia-Reperfusion Injury in Mice
D. Noguchi, N. Kuriyama, T. Fujii, H. Kato, M. Kishiwada, S. Mizuno, M. Usui, H. Sakurai, S. Isaji
Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan
*Purpose: Coagulation cascade is an important pathway in the pathophysiology of hepatic ischemia-reperfusion injury(IRI). Generation of thrombin is a critical factor of coagulation induced by…